Clobazam (Onfi)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy (label: adjunctive treatment of seizures associated with Lennox-Gastaut syndrome, age 2 and older), Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathies

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (8)
Developmental and Epileptic Encephalopathies
NCT02187809 · H. Lundbeck A/S
2015-03 – 2015-10 · Dravet Syndrome
What this study did
NCT02174094 · H. Lundbeck A/S
2015-03 – 2015-08 · Dravet Syndrome
What this study did
Epilepsy
NCT02134366 · The Cooper Health System
2014-07 – 2017-07 · Epilepsia Partialis Continua, Kojewnikov's Epilepsy, Epilepsy
What this study did
Lennox-Gastaut Syndrome
Other / comorbidity
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT01179828 · Insel Gruppe AG, University Hospital Bern
2010-07 – 2015-12 · Low Back Pain
What this study did
NCT01011036 · Insel Gruppe AG, University Hospital Bern
2009-12 – 2010-06 · Pain
What this study did
Phase 2 (3)
Epilepsy
NCT02564952 · Jazz Pharmaceuticals
2016-03-11 – 2017-06-07 · Epilepsy
What this study did
NCT02565108 · Jazz Pharmaceuticals
2016-01-20 – 2016-07-21 · Epilepsy
What this study did
Lennox-Gastaut Syndrome
NCT00162981 · Lundbeck LLC
2005-10 – 2006-10 · Epilepsy, Epilepsy, Generalized, Seizures
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT01291316 · University Hospital, Geneva
2010-04 – 2011-11 · Neuropathic Pain
What this study did
Phase 4 (3)
Epilepsy
NCT03371836 · Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
2017-10-01 – 2019-12-31 · Epilepsy, Anxiety
What this study did
NCT02726919 · Pavel Klein
2015-02 – 2018-06 · Epilepsy
What this study did
NCT01932502 · St. Joseph's Hospital and Medical Center, Phoenix
2013-02 – 2017-09 · Refractory Epilepsy
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT03678129 · King's College London
2018-12-07 – 2025-06-27 · Autism Spectrum Disorder
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 4 (1)
Epilepsy
NCT05697614 · Dr Cipto Mangunkusumo General Hospital
2023-03-01 – 2023-06-30 · Drug Resistant Epilepsy
What this study did

Competitive landscape

This mechanism is crowded: 14 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Developmental and Epileptic Encephalopathies: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Clobazam (Onfi): this drugApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidReliable signal
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT03355209: Percentage change from baseline in drop-seizure frequency, fenfluramine 0.7 mg/kg/day (n=87) vs placebo (n=87): median reduction 26.5 vs 7.6 percentage points; estimated median difference -19.9 percentage points (95% CI -31.0 to -8.7; P=.001).
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT03572933: Median percentage change in 28-day major motor seizure frequency: ganaxolone -30.7% vs placebo -6.9% (p=0.0036); Hodges-Lehmann median difference -27.1% (95% CI -47.9 to -9.6), n=100 (Knight et al., Lancet Neurol 2022).
RufinamideApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
KH607
Phase 3(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication
GlyphAllo (allopregnanolone Prodrug) (SPT-300)
Phase 2(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
HS-10353
Phase 2(overall)
Small moleculeGABA-A receptor
Partial signal(overall)
No reviewed efficacy summary in this indication
Remimazolam
Phase 1(overall)
Small moleculeGABA-A receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Compare side by side

4 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.

Upcoming events

No upcoming readouts on record for this asset.